| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5446194 | ORION PHARMA | Pharmacologically active catechol derivatives |
Oct, 2013
(10 years ago) | |
| US6500867 | ORION PHARMA | Pharmaceutical composition comprising entacapone, levodopa, and carbidopa |
Jun, 2020
(3 years ago) | |
| US6797732 | ORION PHARMA | Pharmaceutical composition comprising entracapone, levodopa, and carbidopa |
Jun, 2020
(3 years ago) | |
Stalevo 100 is owned by Orion Pharma.
Stalevo 100 contains Carbidopa; Entacapone; Levodopa.
Stalevo 100 has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Stalevo 100 are:
- US5446194
- US6500867
- US6797732
Stalevo 100 was authorised for market use on 11 June, 2003.
Stalevo 100 is available in tablet;oral dosage forms.
Stalevo 100 can be used as treatment of parkinson's disease.
The generics of Stalevo 100 are possible to be released after 29 June, 2020.
Drugs and Companies using CARBIDOPA; ENTACAPONE; LEVODOPA ingredient
Market Authorisation Date: 11 June, 2003
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL
How can I launch a generic of STALEVO 100 before it's drug patent expiration?
More Information on Dosage
STALEVO 100 family patents
